ACAD — ACADIA Pharmaceuticals Inc.
7 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about ACAD (2026-11-05)
- ACADIA Pharmaceuticals reported Q3 2026 earnings that beat expectations, with EPS of $0.31 versus the $0.18 estimate.
- Revenue reached $342.3M, surpassing the $333.0M estimate by 2.8%.
- The FDA granted Fast Track designation for remlifanserin to treat Lewy body dementia psychosis.
| GDELT | 3 | news |
| Bluesky | 2 | community |
| RSS Bundle | 1 | news |
| SEC EDGAR 8-K | 1 | filings |